Table 5.

Relative bioavailability of the M3 metabolite with sprinkle vs capsule formulations, and with sprinkle formulation in fed vs fasted states

Comparison	Parameter	Geometric LS mean
		Values	Ratio	90% CI
Sprinkle vs capsule	Cmax (pg/mL), n = 30	129.974 vs 63.566	2.045	1.615, 2.589
	AUC0–t (h·pg/mL), n = 30	167.770 vs 116.426	1.441	1.166, 1.782
	AUC0–∞ (h·pg/mL), n = 8	249.646 vs 196.115	1.273	0.837, 1.937
Sprinkle, fed vs fasted	Cmax (pg/mL), n = 14	48.192 vs 116.815	0.413	0.339, 0.502
	AUC0–t (h·pg/mL), n = 14	135.805 vs 152.900	0.888	0.675, 1.168

AUC area under the concentration–time curve, AUC_0–t from hour 0 to the last measurable concentration, AUC_0–∞ extrapolated to infinity, CI confidence interval, C_max maximum observed concentration, LS least squares, M3 lubiprostone metabolite